Note: Descriptions are shown in the official language in which they were submitted.
:13~ZB'76
BAC~GROUND OF TH~ INVENTIO~ ~
Field of the In~ention
The present invention relates to procedures for the
determination and/or detection of immunologically reactive
analytes such as ligands and ligand receptors. More
particularly, the invention relates to methodology that is
valuable for determining and/or detecting the presence of
threshold levels of analytes such as therapeutic drugs, toxic
materials, drugs of abuse and hormones and the like that are
indicative of a physiological condition. In this latter
regard, in one particularized aspect, the invention relates to
procedures for detecting the presence of threshold levels of
hormones such as progestin and estrogen derivati~es and
luteinizing hormone ~LH) in human urine samples. The invention
also relates to kits of materials for use in conducting such
assay procedures.
escription of the Prior State of the Art
There has long been a need for measuring substances with a
high degree of sensitivity and specificity. In particular, in
fields such a clinical medicine, forensic science,
environmental quality testing, food quality assurance, drug
testing and other related areas, the presence and/or amount of
trace substances in test samples is often of great
significance. In such areas, the measurement of very low
concentrations in the order of parts per million or less is
often necessary. Moreover, such testing or measurement
-- 2 --
13(321~76
generally requires the identification of particular molecules
I
while not sensing other molecules with similar yet different
~ structures.
The need for sensitive and specific tests has been
addressed in the past by the development of a number of
immunoassay procedures based on the highly specific and
sensitive interaction between an antigen and an antibody
directed against such antigen. Antigens and antibodies are
initially recognized as beinq the participants in the immune
process of an animal, that is, when an animal is injected with
a foreign substance that is an antigen, the animal in time
respcnds by producing antibodies which are protein molecules
that recognize and tightly bind the invading antigen thereby
facilitating removal or destruction of the latter. The immune
process is highly specific and the use of immunoassay
procedures for identification of specific substances has been
exploited with great success. Such proceduxes have been
further facilitated by the important discovery of Milstein and
Kohler reported in Nature 256: 495-497, 1975 which concerns the
preparation of so-called monoclonal antibodies. ~he details of
this work are well known and there is no need to repeat the
same here; however, as a result of the Milstein and Kohler
work, the development of highly sensitive and specific reagents
has been particularly facilitated.
-- 3 --
~3VZ~'~6
Known assay procedures include radioimmunoassay (RIA)
procedures, enzyme immunoassays (EIA), enzyme linked
~~ immunosorbant assays (ELISA), fluorescent assays, - -
chemiluminescence assays and assays wherein metal particles
such as gold sol particles are used as tags or labels. These
prior procedures are referred to and described in a commonly
assigned, co-pending application serial no. 105,285, filed
October 7, 1987, the entirety of which is hereby specifically
incorporated by reference.
Some of the known assays operate on the basis of a
competitive immunoreaction. In performing competitive
immunoassays, one generally mixes (1) a first immunoreactive
substance (contained in an unknown sample), (2) a second
immunoreactive substance that is specifically reactive with the
first substance, and (3) a quantity of a third immunoreactive
substance that has immunological reaction characteristics that
are immunospecifically the same as the immunological reaction
characteristics of the first immunoreactive substance. The
third substance carries a detectable tag. During the course of
the immunoreaction, the first and third substances compete with
one another for binding sites on the second substance. After a
predetermined time of immunoreaction, the second substance is
separated and the amount of third substance bound thereto is
determined. If the first substance is initially present at low
leveis, then the amount of third substance and therefore the
amount of detectable tag bound to the second cubstance will be
~3~Z~'~6
elevated. On the other hand, if the amount of first substance
is elevated, then the amount of detectable tag bound to the
second substance via the third substance will be low. Thus, at
all levels, the amount of detectable tag which becomes bound to
the second substance will be inversely proportional to the
- amount of first immunoreactive substance in the sample. At
intermediate levels, the amount of detectable tag bound to the
second substance is monotonically and inversely proportional to
the level of the first immunoreactive substance in the sample.
Competitive immunoassays have found widespread use in
clinical laboratories yielding accurate measurements of a great
number of clinically relevant analytes. However, there are two
features of the competitive assay format that are less than
highly desirable outside of a sophisticated clinical laboratory
setting. First, as discussed above, the resulting signal is
inversely proportional to the amount of substance to be
detected. In the ideal case, however, one would prefer that
elevated levels of analyte should produce elevated levels of
signal. Thus, in a non-instrumental, e.g. visual, examination,
the amount of signal produced would be directly proportional to
the amount of analyte detected. Secondly, in the competitive
immunoassay format described above, the amount of detectable
signal changes as a monotonically decreasing function of the
amount of analyte in the sample. Thus, for analyte levels that
r 25 are very close to one another, only modest shifts in signal
intensity are produced. Such modest shift, although readily
~3~28'76
.
-- detectable with modern instrumentation, may often be too subtle
for reliable detection by the human eye for direct visual
- examination purposes.
Where toxic and/or environmentally undesirable substances
are concerned, once a non-hazardous threshold level has been
selected as a criteria, it is advantageous to use tests which
provide a completely negative result at levels even minutely
below the threshold level and yet provide a clear positive
indication when the level exceeds the selected threshold level.
In a more specific sense, there has long been a need for
simple yet reliable methodology for determining the human
fertile period during the menstrual cycle~ that is, the period
in which viable sperm and a viable ovum may both ~e present in
the reproductive tract of the female. For a variety of
reasons, contraceptive devices and~ materials may not be
available for use, and accordingly, techniques for ascertaining
the fertile period of the menstrual cycle have become
desirable. Manifestly, techniques for ascertaining the fertile
period of the menstrual cycle are valuable both for
intentionally avoiding pregnancy and for facilitating
conception when pregnancy is desired.
The menstrual cycle is governed by the release of hormones
from the female glands and organs. Such release is predictable
and specifically related to ovulation by which ova are released
from the ovaries and the lining of the uterus is made ready for
pregnancy and the hormones and/or metabolites thereof find
~3~Z~3~6
.
their,way into the urine. The specific biqlogical phenomena
are described in detail and with clarity in European Patent
Publication No. 0086095, which was published on August 17, 1983
in European Pat~nt Office Bulletin 83/33. And suf~ice it to
say that during a normal menstrual cycle, the level of estrone-
3-glucuronide (E13G) in female urine begins to rise about 6
days prior to ovulation and reaches its peak about 1 day before
ovulation and falls rapidly during and after ovulation. The
level of pregnanediol-3-glucuronide (P3G) in female urine
begins to rise on the day of ovulation, and reaches a peak 2 to
3 days after ovulation and remains elevated for the duration of
the luteal phase. Likewise, the relationship between P3G and
E13G levels is well known, and from the '095 European patent
publication identified ak~ve, the ratio of estrogen to
progestin metabolites in the urine has been found to be useful
in monitoring the progress of the menstrual cycle.
Of particular importance in following the menstrual cycle
by determining hormonal activity is the fact that approximately
during ovulation, the level of P3G in the urine surges to
levels above 4 ug~ml. Thus, a simple and reliable assay
capable of determining and/or detecting the presence of at
least such threshold amount of -P3G in urine would be extremely
valuable in determining whether ovulation has occurred.
-- 7 --
13~3Z~76
. ~
SUNMAaYQ F T~ INV~NTION
The positive step immunoassay pr~cedure of the present
invention addresses each of the drawbacks inherent in prior art
competitive immunoassays. Firstly, inasmu~h as the reaction is
positive, elevated signals appear in the presence of elevated
analyte levels. Moreover, in accordance with the positive step
function of the immunoassays of the present invention, one does
not observe monotonic decrease (or increase) in signal as a
function of analyte concentration, but rather, the level of
signal unexpectedly rises quite sharply at a preselected
threshold. That is to say, analyte levels just slightly below
the selected threshold result in low or barely detectable
signal levels, while analyte levels just above the threshold
produce the full level of signal attainable with the particular
label that is utilized.
The present invention provides methodology and kits of
materials useful in connection with immunoassays generally. In
particular, the invention provides a positive step assay which
produces a signal in the presence of threshold levels of an
immunoreactive substance. Conventional assays may rely upon
competition between labelled and unlabelled immunoreactive
substances, depending on the format, and the positive step
assay of the present invention reverses the signal so that the
user is able to easily ascertain the presence of the
immunoreactive substance in the sample. Thus, through the use
13V~ 6
.
of the present invention, the detection of surges in the levels
of hormones such as P3G, E13G and LH in urine is facilitated.
The positive step immunoassay format of the present
invention has important application in areas other than
fertility testing. In this regard, there are a variety of
situations in which the determination of the actual amount of a
substance present in a sample may be less significant than
whether the substance is present in an amount that is above or
below a certain threshold level. One example that immediately
presents itself is in the area of forensic testing for
controlled or abused drugs. For example, a threshold value of
0.1% is important in testing for alcohol levels in blood since
values greater than 0.1% are considered to be evidence of
intoxication. Similarly, for marijuana or THC, urine levels of
10, or in other cases 100 ng/ml, are considered to be proof of
substance abuse. Obviously, the positive step immunoassay
formats of the present invention, which produce no color at
analyte levels below a threshold amount and wherein coloration
is achieved at analyte levels above the threshold amount, are
applicable in such context.
The positive step immunoassay of the present invention is
also applicable in the field of therapeutic drug monitoring.
There are a number of highly useful therapeutic drugs such as
theophylline (an antiasthmatic), digoxin (a cardiac regulator)
and aminoglycoside antibiotics, to name a few, which are
- characterized by a therapeutic window. The therapeutic window
_ g _
~3(Jzr~7~
is the range of concentrations of the particular drug from the
minimum level for therapeutic effectiveness up to the level
wherein unwanted or toxic reactions may occur. Clearly, a dual
positive step immunoassay with one assay calibrated to detect
the minimum therapeutic threshold and the other calibrated to
detect the toxic threshold would be extremely valuable.
In accordance with the invention, an immunoassay
procedure is provided to determine the initial presence of at
least a prespecified (threshold) amount of a first
immunoreactive substance in a liquid sample. The procedure
comprises the steps of first establishing an immunochemical
reaction phase by admixing a liquid sample containing an
initially unknown amount of the first immunoreactive substance
with (1) a known amount of a second immunoreactive substance
that is specifically immunoreactive with said first substance
and (2) a quantity of a third immunoreactive substance that has
immunological reaction characteristics which are
immunospecifically the same as the immunological reaction
characteristics of the first immunoreaction substance the third
substance being capable of forming an immunocomposite that is
separable from the reaction mixture. In accordance with the
invention, the known amount of the second substance should be
immunochemically equivalent (just sufficient to immuno-
specifically bind) to the total of the prespecified threshold
amount of the first substance and said quantity of third
immunoreactive substance. Thus, when the amount of the first
immunoreactive substance in the liquid sample solution exceeds
the prespecified threshold amount thereof, unreacted third
--10--
A
~3~Z~376
substance will be available for further immunospecific reaction
in the reaction phase. The reaction phase thus established is
then contacted with a quantity of a fourth immunoreactive
substance that has immunolo~ical reaction characteristics which
-5 are immunospecifically the same as the immunological reaction
characteristics of ths second substance. And the fourth
substance carries a detectable tag. Thus, the initial presence
of more than the prespecified threshold amount of first
substance in the sample may be determined by detecting the
existence of a specific immunoreaction product which contains
the detectable tag.
Preferably, the third immunoreactive su~st~nce w~LL be
bound to a solid support whereby the third immunoreactive
substance is immobilized (such as where the solid support
comprises a permeable membrane), or is rendered collectible
(such as where the solid support comprises a dispersible,
particulate, collectible solid material).
In a preferred form of the invention, the liquid sample
containing the first immunoreactive substance is premixed with
a known amount of a second immunoreactive substance that is
immunospecifically reactive with said first immunoreactive
substance, to thereby produce a first reaction phase. The
first reaction phase is then contacted with a quantity of the
third immunoreactive substance to produce a second reaction
phase. In this form the invention is particularly useful in
13~2~6
performing an assay for small molecules including drugs and
haptens such as P3G and E13G.
In a preferred practical form of the invention for
determining the amount of a first immunoreaction substance in a
liquid sample, the immunoassay procedure of the invention
comprises the steps of furnishing a liquid sample containing an
initially unknown amount of the first immunoreactive substance
and dividing the sample into a plurality of aliquot portions.
Respective different amounts of a second immunoreactive substance
that is specifically immunoreactive with said first
immunoreactive substance are introduced into the aliquot portions
to produce a plurality of first reaction phases, each of which
contains a respective different known amount of the second
substance. The first reaction phases are then contacted with a
quantity of a th rd immunoreactive substance that has
immunological reaction characteristics which are
immunospecifically the same as the immunoreaction characteristic
of the first immunoreactive substance. Thus, a plurality of
second reaction phases are produced, each containing the same
amount of the third substance and respective different amounts of
the second substance the third substance being capable of forming
an immunocomposite that is separable from the reaction mixture.
In accordance with the invention, the respective known amounts of
the second substance in the second reaction phases are
predetermined so as to be immunospecifically equivalent to (just
enough to immunospecifically react with and block) the total of
said quantity of third substance plus a corresponding
, . ,~
.
~3~ZB'~'6 --` -
respective preselected amount of the first substance, whereby,
when the unknown amount of the first substance in the sample is
less than or egual to the corresponding respective preselected
amount thereof, no unreacted third substance will be available
for further immunospecific reaction in the second reaction
phase. And when the unknown amount of the first substance in
the sample is greater than the corresponding respective
preselected amount thereof, unreacted third substance will be
available for further immunospecific reac~ion in the
corresponding second reaction phase. The second reaction
phases are then brought into contact with a quantity of a
labelled fourth immunoreactive substance having immunological
reaction characteristics that are immunospecifically the same
as the immunological reaction characteristics of the second
substance. Thus is produced a plurality of respective
detection phases corresponding respectively to the second
reaction phases, whereby a labelled immunoreaction product will
be formed by specific immunoreaction between unreacted third
substance and labelled fourth substance in each reaction phase
which corresponds to a second phase where the amount of first
substance in the sample exceeds the said corresponding
respective preselected (threshold) amount thereof. The
presence or absence of labelled immunoreaction product may then
be detected in each detection phase as an indication of the
initial presence of at least the corresponding respective
preselected amount of first substance in the sample.
- 13 -
-- 13~3Zl 3~7~
~ `
Through the use of the procedure just described, the
amount of the first immunoreactive substance in the liquid - -
sample may be determined to be within a specific narrow range
depending on the respective calibrated amount of the second
immunoreactive substance that is introduced into the various
reaction phases. That is to say, a first reaction system may
be calibrated so that the corresponding reaction phase will
contain labelled immunoreaction product when the amount of
first immunoreactive substance in the sample is greater than 1
ug/ml, a second reaction system may be calibrated so that the
corresponding reaction phase will contain labelled
immunoreaction product when the level of first immunoreactive
substance in the sample is greater than 2 ug/ml, a third
reaction system may be calibrated so that the correspondin~
reaction phase will contain la~lled immunoreaction product
when the amount of first immunoreactive substance in the liquid
sample exceeds 3 ug/ml, and so on. Thus, and if the procedure
is designed so that the presence of labelled immunoreaction
product in the detection phase produces-coloration, the
detection phases of systems precalibrated to detect levels less
than the determined amount o first immunoreactive substance
will be colored, while the detection phases of the systems
precalibrated to detect levels greater than the determined
amount of,first immunoreactive substance will be free of color.
- 14 -
13~Z~ ~6
In another important aspect of the invention, a kit of
materials is provided for conducting an immunoassay procedure
to detect the presence of at least a predetermined amount of a
first immunoreactive substance in a liquid sample. The kit
comprises a known amount of second immunoreactive substance
that is specifically immunoreactive with the first substance, a
known amount of a third immunoreactive substance that has
immunological reaction characteristics which are
immunospecifically the s me as the immunological reaction
characteristics of the first immunoreactive substance, and an
amount of a labelled fourth immunoreactive substance having
immunological reaction characteristics which are
immunospecifically the same as the immunological reaction
characteristics of the second substance. The third
immunoreactive substance may preferably be bound to a solid
support, and in a particularly preferred aspect of the
invention, the solid support may comprise a dispersible,
particllate, collectible solid material. In an even more
preferred aspect of the invention, the fourth immunoreactive
substance may be labelled using a gold sol particle tag capable
of producing a red coloration on a filter element when
materials containing the tag are collected thereon.
While the present invention is useful in connection with
all immunoreactive substances, that is specific binding
proteins and corresponding bindable substances, the invention
has particular utility in connection with small monoepitopic
-- 15 --
13~Z~ 6
molecules such as drugs and haptens that are hormones and
hormonal metabolites including P3G and E13G and related
materials generated by human females during the menstrual
cycle.
D~SCRIPTION OF TH~ SP~CIFIC ASPECTS OF T9E INVENTIO~
In all of the aspects of the invention se~ forth above,
the third immunoreactive substance that has immunological
reaction characteristics which are immunospecifically the same
as the immunological reaction characteristics of the first
immunoreactive substance will generally be of basically the
same substance as the first immunoreactive substance. That is
to say, if the procedure and/or kit is for the purpose of
determining the initial presence of P3G in a liquid sample, the
third immunoreactive substance will most generally also
comprise P3G. Similarly, the fourth immunoreactive substance
most generally will be the same as the second immunoreactive
substance, each being the same antibody to the hormone. In
this regard, if the first immunoreactive substance is such that
it has multiple immunoreactive sites available for
immunoreaction, the second and fourth immunoreactive substances
should be specifically immunoreactive relative to the same site
or sites.
In accordance with the present invention, the positive
step assay format changes an inverse competitive signal to a
positive step in the presence of increasing levels of hapten or
other immunoreactive substance in the liquid sample.
- 16 -
- 13~Z~'~6
~.-
Additionally, the assay format may be designed to provide apositive signal at a predetermined level of immunoreactive
substance in the liquid sample (for example, the threshold
level of P3G indicating that ovulation has occurred) and no
signal at a lower level. since the physiological detection of
P3G is important between 2.5 and 5 ug/ml in urine samples, the
assay may be constructed, for example, to give no signal at 2.5
ug/ml, but maximal signal at 5 ug/ml of P3G.
The present invention provides an assay procedure and a
kit of materials for determining and/or detecting a variety of
immunological reactive analytes such as ligands and ligand
receptors in aqueous samples. The analytes axe immunoreactive
substances such as mono or polyepitopic ligands, including both
antigens and haptens; however, the invention is particularly
useful in connection with monoepitopic haptens such as hormones
and especially the metabolites of estrogen and progestin
compounds such as E13G and P3G. A characteristic of the
immunoreactive substances with which the present invention is
involved is that the same are capable of immunospecifically
binding another immunoreactive substance. When one
immunoreactive substance is specifically immunoreactive with
another immunoreactive substance, one of the substances, or
molecules, is referred to as the ligand, and the other as the
receptor or anti-ligand. The molecules are different and one
- 17 -
13~ 6
.
has an area on the surface or in a cavity which specifically
binds to a particular spatial and/or polar organization of the
other.
When an immunoreactive substance is admixed with an
immunoreactive substance that is specifically immunoreactive
therewith, the two present an immunochemical reaction phase
which, i~ sufficient time for incubation is available, will
result in the occurrence of a specific immunoreaction between
the two substances so as to generate an immunoreaction product.
Antigenic immunoreactive substances may have one or more
epitopes which are capable of entering into immunospecific
reaction. These epitopes may be the same or different.
However, only those epitopes that are the same are capable of
entering into a specific immunoreaction with a given binding
partner. If an immunochemical reaction phase is allowed to
incubate for a sufficient amount of time, the reaction will go
to equilibrium such that when the amounts of immunospecifically
reactive substances are immunochemically equivalent, no further
sites are available for immunospecific reaction. When this
state is achieved, it can be said that no unreacted
immunoreactive su~stance is available for immunospecific
reaction in the reaction phase. And if one or the other of the
specifically immunoreactive materials is present in an amount
which is greater than the immunochemical equivalent amount,
none of the other immunoreactive substance will be available in
- 18 -
13~ 7~
. .
the reaction phase for further immunospecific reaction. Thus,
such other immunoreactive substance is said to be blocked.
Manifestly, the specific immunochemical equivalency of any
given immunoreactive substance is not a precise, mathematically
calculatable number. Rather, the specific immunochemical
equivalency of any given immunoreactive substance relative to
another immunoreactive substance that is specifically
immunoreactive therewith is generally determined empirically.
This may be done, in the present case, simply by setting up a
number of standards contai~ing different amounts of the unknown
material and determining, by experimentation, the amount of the
other substance it takes to block the first substance. For
example, such determination may be accomplished by titration in
accordance with well-known procedures.
In accordance with the present invention, an
immunoreactive substance is said to have immunological reaction
characteristics which are immunospecifically the same as the
immunological reaction characteristics of another substance
when those two substances are capable of entering into the
identical specific immunochemical reaction. That is to say,
the substances are capable of immunospecific reaction in an
analogous manner. This phenomena may occur, for example, when
one of the substances is a portion of the other substance and
carries the same specific epitope. The phenomena may also
occur when the substances are basically the same but one is
freely mobile in the reaction phase and the other is
-- 19 --
^` 13~ 3'76
immobilized and/or conjugated to a solid phase which
facilitates collection. The phenomena may also be present when
one of the substances is present in its basic and unreacted
form and the other is labelled or tagged with a detectable tag
which facilitates identification and/or quantification as a
part of the assay procedure. Generally speaking, in the case
of the present invention, a hapten which is free in the
reaction phase, and the same hapten which is conjugated to a
solid support, have immunological reaction characteristics
which are immunospecifically the same. Also, an anti-hapten
antibody which is labelled with a detectable tag has
immunological reaction characteristics which are
immunospecifically the same as the immunological reaction
characteristics of the same anti-hapten antibody that is not
labelled. Such-substances may be said to have analogous
immunological reaction characteristics.
In connection with the present in~ention, when the unknown
amounti of immunoreactive substance in the liquid sample exceeds
the prespecified or threshold amount, the result is the
production of a labelled immunoreaction product. The labelled
immunoreaction product may be in the form of an immunoreaction
product (or composite) wh.ich is either immobilized by being
bound to a solid support such as a membrane, or is bound to an
initially dispersed dispersible, particulate, collectible solid
material that has been collected, for example on a filter
element. In either case, the immunoreaction product carries a
- 20 -
13~z~t76
tag which is colored in its own right, such as a gold sol
particle, or which facilitates a color forming reaction, such
as in the case of enzymatic color formation. In enzymatic
color forming systems, the color forming materials are brought
together into a color forming condition by formation of the
immunoreaction product. Such procedures and materials are well
known and need not be discussed in further detail here. The
formation of a detectable color as a result of a gold sol
particle tag is part of the invention disclosed and claimed in
said co-pending application serial no. 105,285, referred to
above. Suffice it to say that the gold sol particles are
collected and concentrated by the formation of the
immunorëaction product and collection of the same such that a
visually observable coloration is formed.
The invention is more fully described with reference to
the following specific examples.
Example 1 - Plate ELISA ~ssay~Usin~ Positive Ste~ Procedure
PreParation of Gelatin - P3G
Pregnanediol-3-glucuronide (P3G) (Sigma) in the free acid
form was covalently coupled to gelatin (Sigma) by the mixed
acid anhydride method, exactly as described by Erlanger et al.,
J. Biol. Chem. 228, 713-727 (1957). By this procedure, the
steroid is joined as a peptide bond via the glucuronide
carboxylic acid to E-amino groups of lysine residues in the
polypeptide chain of the protein.
- 21 -
- ~3(DZ876
.
Attacbm~nt of Gelatin - P3G to Solid SUPDort
Gelatin-P3G prepared as set forth above was passively
` adsorbed to the plates of a PVC 96 well microtiter plate. 50
ul of a gelatin-P3G solution containing 0.250 ug/ml of the
steroid in a solution containing 10 mM KPO4 and 0.145 M NaCl
(pH 7.4) (PBS) was added to each of the wells and the solution
was allowed to stand on the plates in the wells for one hour at
room temperature (22C~. The solution was then decanted from
the wells and the plates were blocked to avoid non-specific
binding by contacting the same with a P8S/0.02% NaAzide
solution (pH 7.2) containing 1% gelatin for a period of one
hour at room temperature. The treated wells~were again
decanted and washed two times with a PBS solution containing
0.1% Tween 20 (v/v) (pH 7.4).
Plate ELISA Assav
Standard solutions containing anti-P3G antibody in PBS
were provided in eight different concentrations, i.e., 1.0,
2.0, 4.0, 8.Q, 16.0, 32.0, 64.0 and 128.0 ug/ml, and sample
solutions containing P3G in PBS were provided in six different
20 concentrations, i.e., 2.5, 1.25, 0.625, 0.3125, 0.156, and 0
ug/ml. 150 ul of each anti-P3G antibody standard solution was
admixed with 30 ul of each P3G sample solution to provide 48
separate reaction phases. Two separate 60 ul portions of each
reaction phase was placed in the wells.
- 22 -
. 13~Z876
.
,..
The solutions were allowed to incubate in the wells for 15
minutes at room temperature. The solutions were then-decanted
- from the wells and the plates were washed two times with a wash
solution comprising 0.1% Tween 20 in PBS. 50 ul of a solution
containing 62.5 ng/ml of an anti-P3G antibody/horseradish
peroxidase (HRP) conjugate (prepared by the well known method
of Nakane et al.) in 0.1 M Tris-acetate (pH 7.0) was added to
each plate and allowed to incubate for 15 minutes at room
temperature. The wells were then washed five times with the
PBS/Tween wash solution to make sure that all non-specifically
bound HRP is removed. iO ul of a color developing substrate
solution comprising a fresh mixture of 3 ml. of 0.125%
tetramethylbenzidine in methanol and 7 ml. of 0.03% hydrogen
peroxide in a 0.1 M phosphate and 50 mM citric acid aqueous
solution (pH 5.0) was added to each plate and allowed to react
for 5 minutes at room temperature. The intensity of the color
formation was read on a Dynatech plate reader (Dynatech,
Virginia) at 630 nm with a reference wave length of 490 nm.
- 23 -
. l3a~z~76
The results are set forth in Table I below:
'
Table I
Concentration of P3G, uq/ml
2.5 1.25 0.625 0.3125 0.156 0
1 0.451 0.572 0.604 0.649 0.688 0.026
1 0.440 0.487 0.587 0.589 0.598 0.028
~ 2 0.714 0.757 0.751 0.744 0.481 0.016
. 2 0.684 0.703 0.725 0.708 0.514 0.018
~ 4 0.468 0.503 0.554 0.576 0.030 0.013
.~ 4 0.505 0.503 0.564 0.549 0.022 0.010
8 0.678 0.695 0.743 0.659 0.016 0.011
~ 8 0.641 0.712 0.750 0.654 0.016 0.010
15 ~ 16 0.478 0.537 0.480 0.011 0.000 0.000
o 16 0.469 0.537 0.521 0.008 0.002 0.002
e 32 0.613 0.619 0.019 0.010 0.004 0.006
h 32 0.633 0.547 0.021 0.011 0.006 0.010
u 64 0.477 0.004 0.004 0.002 0.002 0.000
20 u 64 0.511 0.007 0.004 0.003 0.000
1280.009 0.007 0.007 0.007 0.006 0.011
1280.009 0.008 0.009 0.010 0.012 0.013
This test of Example 1 was arranged to illustrate the
detection and determination of P3G in the sample solutions, and
the detection and determination of whether-the amount of P3G in
- 24 -
~3~Z1~'76
.
.
a given sample solution exceeds a particular known preselected
amount. The P3G in the sample solution may be referred to as a
first immunoreactive substance, the anti-P3G antibody in the
standard solutions may be referred to as a second
immunoreactive substance. The first and second immunoreactive
substances are specifically immunoreactive with one another.
The P3G bound to the plate (a solid support) by gelatin linkage
is a third immunoreactive substance which is analo~ous to the
first immunoreactive substance and thus has immunological
reaction characteristics which are immunospecifically the same
as the immunological reaction characteristics of P3G, the first
immunoreactive substance. The anti-P3G antibody which is
conjugated to HRP is a fourth immunoreactive substance that is
analogous to the second immunoreactive substance and thus has
immunological reaction characteristics which are
immunospecifically the same as the immunological reaction
characteristics of the second substance. The HRP that is
conjugated to the anti-P3G antibody is an enzymatic tag or
label that is capable of being detected by known means and
procedures. Thus, the anti-P3G antibody/HRP conjugate is a
labelled fourth immunoreactive substance.
In the Example 1 illustration, a known amount of anti-P3G
antibody (second immunoreactive substance) is contacted with
preselected amounts of P3G (first immunoreactive substance).
P3G ordinarily will be an analyte to be detected or determined,
but for purposes of the present illustrative example, the P3G
- 25 -
13V28'~
.
:
is present in known amounts. Thus is provided a series of
first reaction phases, each containing respective different
` known amounts of anti-P3G antibody. The first reaction phases
are then each brought into contact with the P3G (third
immunoreactive substance) that is bound to the respective
plates of the microtiter plate to produce a second reaction
phase in each well of the microtiter plate. The plates of the
wells were all contacted by the same P3G-gelatin solution under
identical conditions, and thus the second reaction phases
contain the same amount of P3G bound to the plate and
respective different known amounts of anti-P3G antibody.
In each second reaction phase, if the total known amount
of anti-P3G antibody is sufficient to immunospecifically react
with all of the P3G in the sample and all of the bound P3G, the
bound P3G is said to be blocked by the antibody and further
immunoreaction is prevented. However, if the total amount of
anti-P3G antibody is not sufficient to react with all of the
P3G in the second reaction phase, bound P3G will remain
unblocked and available for further immunospecific reaction.
Thus, when the second reaction phases are washed and contacted
with the anti-P3G antibody/HRP conjugate solution,
immunospecific reaction will occur in those cells where
unblocked bound P3G was present ~where the P3G in the sample
exceeded the calibrated amount) and the HRP enzymatic color
former will be bound to the plate via the immunoreaction
between the unblocked P3G and the antibody/HRP conjugate.
- 26 -
~ 13~
- -
Manifestly, as the amount of P3G in the sample increases, the
ability of a given ~uantity of antibody to block the bound P3G
decreases. At an empirically determinable point, further
increase in P3G in the sample results in the presence of
unblocked P3G on the plate and subsequent binding of HRP to the
plate upon introduction of the labelled antibody. When HRP is
thus bound to the plate, color is formed by addition of the TMB
solution.
In Table I it can be seen (right hand column) that no
color was produced in the cells where there was no P3G in the
sample. (The numerical values in Table I increase directly
with increased color, and the very small numbers indicate very
little color while the relatively much larger numbers indicate
a distinct coloration.) Also, in the bottom row of Table I,
where the known concentration of anti-P3G antibody was 128
ug/ml, no color was produced in any of the cells since this
amount of antibody was sufficient to block all of the P3G, even
when the concentration of P3G in the sample was 2.5 ug/ml.
However, in the case where the antibody concentration was 64
ug/ml, full coloration of the plate occurred when the
concentration of P3G in the sample reached 2.5 ug/ml; where the
antibody concentration was 32 ug/ml, full coloration occurred
at a P3G concentration of 1.25 ug/ml; where the antibody
concentration was 16 ug/ml, full coloration occurred at a P3G
concentration of 0.625 ug/ml; at an antibody concentration of 8
ug/ml, the jump occurred at 0.3125 ug/ml of P3G; and where the
- 27 -
~- 13~2~'76
. . .
..
antibody concentration was 1 or 2 ug/ml, the jump occurred at
0.156 ug/ml of P3G. Manifestly, it can be seen that the jump
point from no color to full color is extremely sensitive and
may be adjusted and calibrated empirically simply by modifying
the amount of anti-P3G antibody in the standard solution and/or
the amount of P3G bound to the support.
~ample 2 - Flow Through ELISA Assay Using
Positive SteP Procedure
PreParation of Membrane
A microporous flow through membrane was used to support a
solid phase immobilized reactant in this example. The membrane
used was a Pall immunoaffinity membrane of the sort described
in U.S. lettexs patent no. 4,066,512. The membrane was
prepared by spotting the same with 3 ul of a solution
containing gelatin-P3G prepared as described above in Example l
and 100 ug/ml of glucose oxidase in PBS. In all, five sets of
spotted membranes were prepared using different concentrations
of gelatin-P3G, i.e., 10, 1, 0.1, 0.01 and 0.001 uglml. The
spotted membranes were blocked to avoid nonspecific binding
using 2 ml of a solution containing 0.5% Carnation milk and
0.02% Tween 20 in PBS (pH 7.4). The membranes were then
installed in flow through devices of the type described in
commonly assigned, co-pending application, serial no. 107,240,
filed October 13, 1987.
- 28 -
13~Z~3'76
: .
Flow Tbroug~ Assay
An anti-P3G antibody standard solution containing 32 ug/ml
of the antibody in PBS, and sample solutions containing
respectively 2.5, 1.25 and 0 ug/ml of P3G in PBS were provided.
40 ul of each sample solution was premixed with 400 ul of the
antibody standard solution and the mixtures were poured
separately onto and through the membrane of a respective flow
through device prepared as described above. 400 ul an anti-
P3G antibody/HRP conjugate solution prepared as described in
Example 1 was then poured through each membrane and the
membranes were washed with 1 ml of a wash solution containing
3% Igepal and 1% sodium dodecyl sulphate in P~S. The membranes
were then contacted with 0.4 ml of a substrate solution
consisting of an admixture of 7 parts of a solution containing
7.0% dextrose and 0.01% TM3 in 0_034 M citrate 0.071 M sodium
phosphate and 3 parts methanol. The results, evaluated
visually after 3 to 5 minutes, did not vaLy with the
concentration of the spotting solution, and were as follows:
P3G ~uq/ml) Readinq
2.5 + (blue color)
1.25
O
-- 29 --
` 13~213~6
,
; - ~xan~le 3 - Sol Capture Assay Using Positive
Ste~ Procedure
- PreParation of Solid Phase Particles
.
A latex-gel-P3G dispersion was prepared by covalently
coupling P3G to gelatin as set forth above (Example 1) and
coupling the gelatin-P~G component to Polybead carboxylate
monodisperse microspheres using exactly the same procedure as
is described in Example II~g) of said application serial no.
105,285 cited above. A series of sample solutions,
respectively containing 0.625, 1.25, 2.5, 5.0, 10 and 20 ug/ml
of P3G in PBS, were provided. 20 ul of each sample solution
was premixed with 300 ul of the antibody standard solution
described in Example 2 above, and 20 ul of the latex-gel-P3G
dispersion was thereafter added to each pre-mixed p~ase. The
reaction mixture was then poured through a filter made of
regenerated cellulose (1 micron) to capture and collect the
latex particles. Gold sol particle labelle~ anti-P3G antibody
was pr~pared as described in Example II(b) of said co-pending
application serial no. 105,285, and the gold labelled antibody
was suspended in a solution containing 40 mM MgS04, 1% BSA and
0.02% NaAzide. The mixture was poured through the filter where
the latPx particles were collected and the filter was washed
with a wash solution containing 1.234 mM Thimerosal, 3% Igepal
CA720 and 1% sodium dodecyl sulphate in PBS (pH 7.2~. The
- 30 -
~ 3~2~
- visual results were as follows:
P3G ~ua/ml) Reading
0.625
1.25
2.5
5.0 ~ (pink color)
10.0 + "
20.0 + "
10Thus, when the P3G in the sample exceeded 2.5 ug/ml, the
blocking antibody was expended and at least a portion of the
P3G coupled with the latex remained unblocked. After the latex
beads were collected on the filter, the unblocked P3G-latex on
the filter was able to react with the gold sol particle
labelled anti-P3G antibody, and a collected latex-P3G-anti-P3G-
gold immunocomplex was formed. This collected complex on the
filter presented a visually observable pink coloration. On the
other hand, when the P3G in the sample was 2.5 ug/ml or less,
the blocking antibody was available to block all the P3G-latex
and the gold labelled antibody simply remained uncomplexed and
in dispersion and in such form that it readily flowed through
the filter.
The foregoing Example 3 was repeated using glass particles
for the solid phase instead of latex particles, and essentially
identical results were obtained.
13~2~76
.
.-- Exampl~ 4
Procedures essentially the same as the procedures of
Examples 1 through 3 were conducted for assaying for estrone-3-
glucuronide (E13G). In such assays Bovine Serum Albumin
(fraction 5) was used rather than gelatin to link the hapten to
the solid support. The BSA linkage procedure is described by
Erlanger et al. (supra). The assay results obtained were
essentially identical to the results obtained in Examples 1 to
3.
In a practical environment, the P3G and E13G assays of the
present invention may be used to predict ovulation in advance,
verify ovulation, assess luteal function, detect the beginning
and end of the fertile period assess follicular phase and
diagnose pregnancy. The assays may generally be conducted
using.first morning urine (FMU).
The P3G assay may be used to measure the increase in P3G
in FMU during ovulation and during the luteal phase and can be
calibrated to provide a positive color indication when P3G
rises above the threshold level of about 4 ug/ml~ The color
(showing P3G level above 4 ug/ml) remains throughout the luteal
phase to indicate the length and adequacy of the ovulation
process.
- 32 -
3~Z~76
The E13G assay may be used to detect the increase of the
E13G level in FMU 3 to 6 days prior to ovulation. The assay IS
.
~i. similar to the P3G assay and may be used to show E 13G levels
greater than 30 to 50 ng~ml as an indication that ovulation is
imminent.
- 33 -
